Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 688

Sort by

Sort Order Select

Journal Articles

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

Hanna Kirchhoff, Uemran Karsli, Caroline Schoenherr, Karin Battmer, Sergej Erschow, Steven R. Talbot, Doris Steinemann, Michael Heuser, Olaf Heidenreich, Denise Hilfiker-Kleiner, Arnold Ganser, Matthias Eder, Michaela Scherr

Blood (2021) 137 (19): 2657–2661.

https://doi.org/10.1182/blood.2020008544

Published: 2021

Includes: Supplemental data

Journal Articles

Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases

Manik C. Ghosh, De-Liang Zhang, Wade H. Ollivierre, Audrey Noguchi, Danielle A. Springer, W. Marston Linehan, Tracey A. Rouault

Blood (2021) 137 (18): 2509–2519.

https://doi.org/10.1182/blood.2020009138

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat cold agglutinin disease

Sigbjørn Berentsen

Blood (2021) 137 (10): 1295–1303.

https://doi.org/10.1182/blood.2019003809

Published: 2021

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Heinz Ahlert, MSc, BSc, Sanil Bhatia, PhD, Marc Remke, MD, Melf Sönnichsen, M.Sc., Niklas Dienstbier, M.Sc., Ute Fischer, PhD, Julia Hauer, MD, Arndt Borkhardt, MD

Blood (2019) 134 (Supplement_1): 3883.

https://doi.org/10.1182/blood-2019-128136

Published: 2019

Journal Articles

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Graca M. Dores, MD, Rochelle E. Curtis, MA, Nicole H. Dalal, BA, Martha S. Linet, MD MPH, Lindsay M. Morton, PhD

Blood (2019) 134 (Supplement_1): 4034.

https://doi.org/10.1182/blood-2019-124831

Published: 2019

Journal Articles

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Eloisi Caldas Lopes, PhD, Tai Wang, PhD, David S Jayabalan, MSc, Tony Taldone, PhD, Jorge Monge, MD, Jorge Contreras, MD, Yip Winnie, Vicenta Trujillo, PhD, Panchal Palak, Nicholas Lombardi, Sharma Sahil, PhD, Digwal Chander, PhD, Morton Coleman, MD, Gabriela Chiosis, PhD, Ruben Niesvizky, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 4399.

https://doi.org/10.1182/blood-2019-125267

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia

Orsola Di Martino, PhD, Margaret Y Ferris, MD PhD, Hadwiger Gayla, Haixia Niu, PhD, John S. Welch, MD PhD

Blood (2019) 134 (Supplement_1): 2677.

https://doi.org/10.1182/blood-2019-128869

Published: 2019

Journal Articles

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Nigel Brooks, PhD, Meera Raja, PhD, Barbara W Young, PhD, Gary J Spencer, PhD, Tim CP Somervaille, MD PhD, Neil A Pegg, PhD

Blood (2019) 134 (Supplement_1): 2560.

https://doi.org/10.1182/blood-2019-124707

Published: 2019

Journal Articles

Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing

Llucia Albertí Servera, PhD, Sofie Demeyer, PhD, Inge Govaerts, MD PhD, Olga Gielen, Heidi Segers, MD PhD, Anne Uyttebroeck, MD, Nancy Boeckx, Johan A. Maertens, MD PhD, Kim De Keersmaecker, PhD, Jan Cools, PhD

Blood (2019) 134 (Supplement_1): 2749.

https://doi.org/10.1182/blood-2019-123046

Published: 2019

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Romika Kumari, PhD, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Juha Lievonen, MD, Raija Helena Silvennoinen, MD PhD, Pekka Anttila, MD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3069.

https://doi.org/10.1182/blood-2019-128181

Published: 2019

Journal Articles

BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma

Changying Jiang, PhD, Yang Liu, MD, Joseph Mitchell McIntosh, Angela Leeming, Rongjia Zhang, William Lee, Krystle Nomie, PhD, Ingrid Karlsson, PhD, Linda Mårtensson, PhD, Mathilda Kovacek, Ingrid Teige, PhD, Björn Frendéus, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 2863.

https://doi.org/10.1182/blood-2019-126957

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression

Jie Jin, PhD, Shujuan Huang, Jiajia Pan

Blood (2019) 134 (Supplement_1): 5048.

https://doi.org/10.1182/blood-2019-125231

Published: 2019

Journal Articles

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Lei Guo, PhD, Jia Li, PhD, Hongxiang Zeng, PhD, Anna Guzman, Tingting Li, MD, Minjung Lee, MS, Yubin Zhou, PhD, Clifford Stephan, Peter J.A Davies, Margaret Goodell, PhD, Deqiang Sun, PhD, Mark A. Dawson, PhD MBBS, Yun Huang, PhD

Blood (2019) 134 (Supplement_1): 5053.

https://doi.org/10.1182/blood-2019-130586

Published: 2019

Journal Articles

Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark

Niels Abildgaard, MD, Anders Waage, MD PhD, Markus Hansson, MD PhD, Pekka Anttila, MD, Mate Szilcz, Yuanjun Ma, Katrine Hass Rubin, Lill-Brith von Arx, Sigurd Ørstavik, Nawal Bent-Ennakhil, Jonatan Freilich, François Gavini, Anders Green

Blood (2019) 134 (Supplement_1): 5030.

https://doi.org/10.1182/blood-2019-121953

Published: 2019

Journal Articles

Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study

Markus Hansson, MD PhD, Niels Abildgaard, MD, Anders Waage, MD PhD, Pekka Anttila, MD, Anders Green, Katrine Hass Rubin, Lill-Brith von Arx, Mate Szilcz, Yuanjun Ma, Sigurd Ørstavik, Nawal Bent-Ennakhil, Jonatan Freilich, François Gavini

Blood (2019) 134 (Supplement_1): 5037.

https://doi.org/10.1182/blood-2019-121983

Published: 2019

Journal Articles

Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction

Ersi Voskaridou, Mantzou Aimilia, PhD, Pagona Flevari, MD, Maria Dimopoulou, MD, Veroniki Komninaka, MD, Konstantina Repa, MD, Ioannis Papassotiriou, PhD

Blood (2019) 134 (Supplement_1): 4829.

https://doi.org/10.1182/blood-2019-122524

Published: 2019

NARROW

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases

How I treat cold agglutinin disease

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Population-Based, Cause-Specific Risk of Non-Lymphoma Deaths Among 20,491 Adults with Classical Hodgkin Lymphoma (cHL) Treated with Initial Chemotherapy in the United States, 2000-2015

Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Evolution of Clinically Relevant Subclones during Chemotherapy Treatment of ALL As Determined By Single-Cell DNA and RNA Sequencing

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

A Novel Role for Malate Dehydrogenase 1 in Acute Myeloid Leukemia Progression

A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells

Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark

Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study

Soluble P-Selectin Levels in Patients with Sickle Cell Disease Reflect Platelets' Activation Rather Than Endothelial Dysfunction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only